» Articles » PMID: 23188829

Epidermal Growth Factor Promotes Protein Degradation of Epithelial Protein Lost in Neoplasm (EPLIN), a Putative Metastasis Suppressor, During Epithelial-mesenchymal Transition

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2012 Nov 29
PMID 23188829
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Aberrant expression of EGF receptors has been associated with hormone-refractory and metastatic prostate cancer (PCa). However, the molecular mechanism for EGF signaling in promoting PCa metastasis remains elusive. Using experimental models of PCa metastasis, we demonstrated that EGF could induce robust epithelial-mesenchymal transition (EMT) and increase invasiveness. Interestingly, EGF was found to be capable of promoting protein turnover of epithelial protein lost in neoplasm (EPLIN), a putative suppressor of EMT and tumor metastasis. Mechanistic study revealed that EGF could activate the phosphorylation, ubiquitination, and degradation of EPLIN through an extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent signaling cascade. Pharmacological inhibition of the ERK1/2 pathway effectively antagonized EGF-induced EPLIN degradation. Two serine residues, i.e. serine 362 and serine 604, were identified as putative ERK1/2 phosphorylation sites in human EPLIN, whose point mutation rendered resistance to EGF-induced protein turnover. This study elucidated a novel molecular mechanism for EGF regulation of EMT and invasiveness in PCa cells, indicating that blockade of EGF signaling could be beneficial in preventing and retarding PCa metastasis at early stages.

Citing Articles

EPLIN, a prospective oncogenic molecule with contribution to growth, migration and drug resistance in pancreatic cancer.

Zeng J, Wang C, Ruge F, Ji E, Martin T, Sanders A Sci Rep. 2024; 14(1):30850.

PMID: 39730634 PMC: 11680852. DOI: 10.1038/s41598-024-81485-w.


Expression and molecular insights of lima1 in cholangiocarcinoma.

Obulkasim H, Adili A, Liu Y, Duan S Cell Adh Migr. 2024; 18(1):4-17.

PMID: 39076043 PMC: 11290767. DOI: 10.1080/19336918.2024.2383068.


LIMA1 links the E3 ubiquitin ligase RNF40 to lipid metabolism.

Liu Z, Fan K, Abudukeremu A, Gao M, Tan X, Mao X Cell Death Discov. 2024; 10(1):298.

PMID: 38909032 PMC: 11193757. DOI: 10.1038/s41420-024-02072-6.


Exploring the Enigma: The Role of the Epithelial Protein Lost in Neoplasm in Normal Physiology and Cancer Pathogenesis.

Lindell E, Zhang X Int J Mol Sci. 2024; 25(9).

PMID: 38732188 PMC: 11084159. DOI: 10.3390/ijms25094970.


MAD2 activates IGF1R/PI3K/AKT pathway and promotes cholangiocarcinoma progression by interfering USP44/LIMA1 complex.

Jiang W, Yang X, Shi K, Zhang Y, Shi X, Wang J Oncogene. 2023; 42(45):3344-3357.

PMID: 37752233 DOI: 10.1038/s41388-023-02849-6.


References
1.
Gleave M, Hsieh J, Gao C, Von Eschenbach A, Chung L . Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 1991; 51(14):3753-61. View

2.
Zhau H, Chang S, Chen B, Wang Y, Zhang H, Kao C . Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci U S A. 1996; 93(26):15152-7. PMC: 26372. DOI: 10.1073/pnas.93.26.15152. View

3.
Sanders A, Ye L, Mason M, Jiang W . The impact of EPLINα (Epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis. Angiogenesis. 2010; 13(4):317-26. DOI: 10.1007/s10456-010-9188-7. View

4.
Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y . Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer. 2011; 11:31. PMC: 3040720. DOI: 10.1186/1471-2407-11-31. View

5.
Maul R, Song Y, Amann K, Gerbin S, Pollard T, Chang D . EPLIN regulates actin dynamics by cross-linking and stabilizing filaments. J Cell Biol. 2003; 160(3):399-407. PMC: 2172667. DOI: 10.1083/jcb.200212057. View